We use cookies on our website. Some are necessary for the operation of the website. You can also allow cookies for statistical purposes. You can adjust the data protection settings or agree to all cookies directly.
Data Protection Declaration
Imprint
Zoonoses Anticipation and Preparedness Initiative (ZAPI)
Project
Project code: FLI-INNT+IVD-08-HV-0024
Contract period: 01.03.2015
- 01.02.2020
Purpose of research: Networks and research co-ordination
ZAPI aims to shorten the time to adequately respond to emerging infectious diseases using a ‘One Health’ approach. The project will yield platforms for the rapid identification and production of viral domains that can be used as veterinary vaccines and will yield platforms for the rapid development, selection and production of protective antibodies to protect the human population. The project will not only aim at rapid development of these products, but also ensure fast track registration and implementation of the control tools as soon as possible after pathogen emergence. To develop these pipelines, the project will focus on three priority pathogens: 1) Rift Valley fever virus (RVFV) 2) Schmallenberg virus (SBV) 3) Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Specific major aims of ZAPI: - Platforms that are suitable for rapid surge production of vaccines - Platforms that allow the rapid identification and production of antibodies capable of neutralizing emerging viruses - Development of release assays that do not make use of animals - Development of protocols for fast-track registration of developed products.
Vaccination of alpacas against Rift Valley fever virus: Safety, immunogenicity and pathogenicity of MP-12 vaccine. Rissmann et. al. 2017 Jan 23;35(4):655-662. doi: 10.1016/j.vaccine.2016.12.003 The amino terminal subdomain of glycoprotein Gc of Schmallenberg virus: disulfide bonding and structural determinants of neutralization Roman-Sosa et. al. 2017 Jun;98(6):1259-1273. doi: 10.1099/jgv.0.000810. Journal of General Virology
Section overview
Subjects
- Animal health
Framework programme
Funding programme
Excutive institution
FLI - Institute for Novel and Emerging Infectious Diseases (FLI-INNT)
Participating institutions
- University of Veterinary Medicine Hannover (TiHo)
- FLI - Institute of Diagnostic Virology (FLI - IVD)
- University of Utrecht
- Erasmus Medical Center (EMC)
- Institut Pasteur
- Institute of Virology, University Medical Centre Bonn
- Viroclinics Biosciences B.V.
- Boehringer Ingelheim Veterinary Research Center GmbH & Co. KG (BIVRC)
